Bladder Small Cell Neuroendocrine Carcinoma Recruiting Phase 1 Trials for Docetaxel (DB01248)

IndicationStatusPhase
DBCOND0113275 (Bladder Small Cell Neuroendocrine Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03582475Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateTreatment